Drug Take-Back Programs Likely To Grow As Supreme Court Denies PhRMA Petition
This article was originally published in The Pink Sheet Daily
More than 250 pharma companies participating in take-back project in Alameda while Exelixis has individual program for Cometriq.
You may also be interested in...
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.
CooperSurgical is hit with second letter for misleading promotion of its copper-containing intrauterine contraceptive. Video lacked any safety information, agency says in request for corrective communication.